Ads
related to: dristan nasal spray discontinued
Search results
Results From The WOW.Com Content Network
The Dristan inhaler has since been discontinued. Furthermore, Wyeth was acquired by Pfizer in 2009. All products currently sold under the Dristan brand are manufactured by Foundation Consumer Brands; Foundation Consumer Brands acquired the Dristan brand in 2020. [75] Foundation Consumer Brands is itself owned by Kelso & Company.
Dristan is an American brand of medications that is made by Foundation Consumer Brands. Dristan 12-Hour Nasal Spray is a nasal decongestant , the active ingredient of which is oxymetazoline hydrochloride 0.05%. [ 1 ]
Oxymetazoline, sold under the brand name Afrin among others, is a topical decongestant and vasoconstrictor medication. It is available over-the-counter as a nasal spray to treat nasal congestion and nosebleeds, as eye drops to treat eye redness due to minor irritation, and (in the United States) as a prescription topical cream to treat persistent facial redness due to rosacea in adults.
A decongestant, or nasal decongestant, is a type of pharmaceutical drug that is used to relieve nasal congestion in the upper respiratory tract. The active ingredient in most decongestants is either pseudoephedrine or phenylephrine (the latter of which has disputed effectiveness ).
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
U.S. health officials on Friday approved a nasal spray to treat severe allergic reactions, the first needle-free alternative to shots like EpiPen. The Food and Drug Administration said it approved ...
Decongestant nasal sprays are advised for short-term use only, preferably 5 to 7 days at maximum. Some doctors advise to use them 3 days at maximum. A recent clinical trial has shown that a corticosteroid nasal spray may be useful in reversing this condition. [3] Topical nasal decongestants include: Oxymetazoline; Phenylephrine; Xylometazoline
The nasal spray was first approved by the FDA in 2019 as a supplemental treatment, along with an oral medication, for the approximately one-third of people with MDD who struggle with treatment ...